Dr Adrian Woolfson

 Non-Executive Director

Dr Woolfson is the founder of ProteinLogic, having discovered soluble Cluster of Differentiation antigens that underpin ProteinLogic’s platform technology. Dr. Woolfson completed his post-graduate training in internal medicine at Addenbrooke’s Hospital, Cambridge, UK. He holds a BM BCh degree in Clinical Medicine from Oxford University and completed his PhD in molecular immunology at Cambridge University. He was the Charles and Katherine Darwin Research Fellow at Darwin College Cambridge, and a Wellcome Trust Clinical Research Fellow. He completed his doctoral and post-doctoral work in the laboratory of Nobel Prize winner and inventor of monoclonal antibodies Dr César Milstein in the Division of Protein and Nucleic Acid Chemistry at the MRC Laboratory of Molecular Biology in Cambridge, UK.

He is currently serving as Executive Vice President of Research & Development, Sangamo Inc., CA, USA. Dr. Woolfson has over a decade of biopharmaceutical industry experience in drug discovery, medical affairs and early and late stage clinical development. Previously, he served as Chief Medical Officer at Nouscom AG, a genetic cancer vaccine biotechnology company based in Basel, Switzerland, where he led the development of the company’s off-the-shelf and personalized neoantigen vaccine and oncolytic virus strategy. Prior to Nouscom, Dr. Woolfson served as Global Clinical Leader, Early and Late Stage Immuno-Oncology/Hematology at Pfizer Inc. in New York, and was responsible for defining Pfizer’s hematology immuno-oncology strategy and building its immuno-oncology hematological malignancies portfolio. Prior to that he was the Global Lead for Pfizer’s SMO inhibitor glasdegib, which received FDA approval in 2018. From 2007 to 2013, Dr. Woolfson held roles of increasing responsibility at Bristol-Myers Squibb, including Global Medical Lead for a first-in-human CDC7 inhibitor and selective JAK2 inhibior.

Mr Peter Klimt

Non-Executive Chairman

Mr Klimt is an experienced entrepreneur with extensive practical expertise in international business including investment, and mergers and acquisitions.

He has professional qualifications in law and practised as a corporate lawyer. He is currently CEO of Welbeck Investment Management Limited.